Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib (N) has proven more potent than L. However, the efficacy o...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:NPJ Breast Cancer
Prif Awduron: Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8159999/
https://ncbi.nlm.nih.gov/pubmed/34045483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00274-0
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg